TGF-ß inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas' heart disease

Ferreira, Roberto Rodrigues; Abreu, Rayane da Silva; Pereira, Glaucia Vilar; Degrave, Wim; Meuser-Batista, Marcelo; Ferreira, Nilma Valéria Caldeira; Moreira, Otacílio da Cruz; Gomes, Natália Lins da Silva; Mello de Souza, Elen; Ramos, Isalira P.; Bailly, Sabine; Feige, Jean-Jacques; Lannes-Vieira, Joseli; Araújo-Jorge, Tania C. de; Waghabi, Mariana Caldas.
Artículo en Inglés | ARCA | ID: arc-40490

Documentos relacionados

  1. In Chagas disease, transforming growth factor beta neutralization reduces <i>Trypanosoma cruzi</i> infection and improves cardiac performance.
  2. The Search for Biomarkers and Treatments in Chagas Disease: Insights From TGF-Beta Studies and Immunogenetics.
  3. Development of small molecule inhibitors targeting TGF-ß ligand and receptor: Structures, mechanism, preclinical studies and clinical usage.
  4. Isoform-selective TGF-ß3 inhibition for systemic sclerosis.
  5. In situ expression of regulatory cytokines by heart inflammatory cells in Chagas' disease patients with heart failure.
  6. Biomedical research in france and brazil: an analysis of significant differences and ethical issues
  7. TGF-ß inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas' heart disease.
  8. Reparative macrophage transplantation for myocardial repair: a refinement of bone marrow mononuclear cell-based therapy.
  9. Platinossomose em felino doméstico no município de Pelotas, RS, Brasil
  10. Transforming growth factor-ß as a therapeutic target for the cardiac damage of Chagas disease.